



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

Date: March 6, 2009
To: Primary Clinical Research Associates
From: Lynn Flickinger
Re: N083E, Phase II Safety Study of Docetaxel and Carboplatin in Combination with Trastuzumab and Lapatinib in Early Breast Cancer

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

Please note that this study was approved by the National Cancer Institute on February 18, 2009.

If you have any questions, please contact Lynn Flickinger (flickinger.lynn@mayo.edu or telephone at 507-538-7035).

Attachments